期刊
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
卷 64, 期 10, 页码 935-951出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s00228-008-0538-y
关键词
Proton pump inhibitors; Pharmacokinetics; Pharmacodynamics; Peptic ulcer; Reflux disease; Helicobacter pylori infection
资金
- Robert Bosch Foundation, Stuttgart, Germany
- Eisai Europe Ltd., London
Background Proton pump inhibitors (PPIs) represent drugs of first choice for treating peptic ulcer, Helicobacter pylori infection, gastrooesophageal reflux disease, nonsteroidal anti-inflammatory drug ( NSAID)-induced gastrointestinal lesions ( complications), and Zollinger-Ellison syndrome. Results The available agents (omeprazole/esomeprazole, lansoprazole, pantoprazole, and rabeprazole) differ somewhat in their pharmacokinetic properties (e.g., time-/dose-dependent bioavailability, metabolic pattern, interaction potential, genetic variability). For all PPIs, there is a clear relationship between drug exposure ( area under the plasma concentration/ time curve) and the pharmacodynamic response ( inhibition of acid secretion). Furthermore, clinical outcome ( e. g., healing and eradication rates) depends on maintaining intragastric pH values above certain threshold levels. Thus, any changes in drug disposition will subsequently be translated directly into clinical efficiency so that extensive metabolizers of CYP2C19 will demonstrate a higher rate of therapeutic nonresponse. Conclusions This update of pharmacokinetic, pharmacodynamic, and clinical data will provide the necessary guide by which to select between the various PPIs that differ-based on pharmacodynamic assessments-in their relative potencies ( e. g., higher doses are needed for pantoprazole and lansoprazole compared with rabeprazole). Despite their well-documented clinical efficacy and safety, there is still a certain number of patients who are refractory to treatment with PPIs (nonresponder), which will leave sufficient space for future drug development and clinical research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据